Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
Demo Company

Bacteriophage Protein Shows Antibiotic Potential

By BiotechDaily International staff writers
Posted on 27 Nov 2013
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
The T7 bacteriophage produces a protein that blocks Escherichia coli cell division and has the potential of being developed into an antibiotic-replacing drug.

T7 produces over 100 progeny per host cell in less than 25 minutes. If the T7 phage infection completes a successful growth cycle, it invariably culminates in disintegration of the host cell. Bacteriophages take over host cell resources primarily via the activity of proteins expressed early in infection. One such protein produced by the T7 phage is called Gp0.4 (gene product 0.4).

Investigators at Tel Aviv University (Israel) and their colleagues at Duke University (Durham, NC, USA) reported in the November 11, 2013, online edition of the journal, Proceedings of the National Academy of Sciences of the United States of America (PNAS) that Gp0.4 was a direct inhibitor of the E. coli filamenting temperature-sensitive mutant Z division protein.

They showed that a chemically synthesized Gp0.4 bound to purified filamenting temperature-sensitive mutant Z protein and directly inhibited its assembly in vitro. Consequently, expression of Gp0.4 in vivo was lethal to E. coli cultures and resulted in bacteria that were morphologically elongated. Furthermore, the inhibition of cell division by Gp0.4 enhanced the bacteriophage’s competitive ability by enabling them to maximize their progeny number by inhibiting escape of the daughter cells of the infected bacteria.

“Bacteria are infested with bacteriophages, which are their natural enemies and which in most cases destroy them,” said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. “Ever since the discovery of bacteriophages in the early 20th century, scientists have understood that, on the principle of the "enemy of your enemy is your friend"; medical use could be made of phages to fight bacteria.”

“GP0.4 impedes cell division in the E. coli cell. With its capacity for cell division blocked, the bacterium continues to elongate until it dies,” said Dr. Qimron. “Potentially, this protein could be the ideal antibiotic.”

Related Links:

Tel Aviv University
Duke University



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The ChilliBlock modular system for precise, controlled cooling and heatingof biological samples (Photo courtesy of Asynt).

Modular Cooling/Heating System Safeguards Temperature-Sensitive Biological Samples

A new modular system designed for precise, controlled cooling and heating of biological samples in microplates, vials and Eppendorf tubes is now available for biotech, clinical, and life science laboratories.... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.